Large Volume Parenteral (LVP) Market Size (2024 - 2029)

Large Volume Parenteral (LVP) Market Analysis

The Global Large Volume Parenteral (LVP) Market size is expected to grow from USD 9.96 million in 2023 to USD 12.55 million by 2028, at a CAGR of 4.70% during the forecast period.

COVID-19 significantly impacted the LVP market due to the increased utilisation of dextrose, lactated ringer injection, ringer injection, and sodium chloride injection among COVID-19-infected patients to maintain their fluid balance. This significantly raised the demand for LVP during the pandemic. For instance, according to the January 2022 update by U.S Pharmacist, the National Institutes of Health recommended the use of balanced crystalloid solutions, such as lactated Ringer's solution, Plasma-Lyte, and Normosol-R, for acute resuscitation of adults with shock and COVID-19. Thus, such an increase in the utilisation of LVPs created a considerable demand, thereby augmenting the market growth during the pandemic. However, in the post-pandemic situation, due to the decline in COVID-19 cases, the use of LVP in COVID-19 patients has also reduced. Besides, the market is expected to grow steadily due to the increased adoption of LVPs in hospitals to treat malnutrition and complications associated with electrolyte and fluid loss.

Factors such as the rising number of surgical procedures and increase in chronic diseases that require fluid replacement therapy are expected to drive the market growth over the forecast period as LVP of dextrose, lactate ringer solutions etc., maintain organ perfusion (hemodynamics) and substrate (oxygen, electrolytes, among others) delivery, which thereby beneficial in patient's overall health outcome. Additionally, the increasing patient pool suffering from chronic disease is one of the major drivers in the large volume parenteral market. For instance, according to the data published by the Australian Institute of Health and Welfare in March 2022, almost half (47%, or 11.6 million) of Australians had one or more common chronic health conditions, including diabetes, cancer, mental and behavioural conditions, and chronic kidney disease in 2021. Chronic illness like cancer is often associated with the occurrence of pain, and therapeutic injections are most commonly used to administer to reduce the pain. Also, these patients must need a proper balance of vital nutrients that help maintain their hydration level, energy, and strength. Thus, administering nutrients through LVPs for chronic disease patients is expected to fuel the market growth over the forecast period.

Additionally, fluid replacement is recommended in haemorrhage, extensive burns, excessive sweating (from a prolonged fever), and prolonged diarrhoea (cholera). Also, bodily fluids can be lost because of surgery, injury, dehydration, disease, or other conditions. In addition, traffic accidents are a significant cause of injury worldwide, as mostly the victim have heavy blood loss in the accident and needs immediate medical attention, which comes under the emergency transfusion procedures and will also impact the LVP market. For instance, according to the Road Accident Statistics in India 2021, more than 412 thousand road accidents were reported by the Police Departments of States and Union Territories (UTs) in India during 2021, causing injuries to more than 384 thousand persons. Thus, owing to the high prevalence of injury cases, the demand for fluid replacement due to bleeding will likely rise, contributing to the market growth over the study period. Moreover, the traumatic injuries that occurred due to accidents led to the increased demand for nutritional updates. For instance, according to the article published in October 2022 in Frontiers Journal, mild traumatic brain injury can increase the nutritional needs of the body, and the administration of vitamin D (100,000 International units (IU)) given as injection via intramuscularly significantly found to improve the vitamin D levels.

Therefore, due to the high prevalence of chronic conditions, increase in injury cases and benefits offered by the LVP in nutrition management, the studied market is expected to witness notable growth over the forecast period. However, challenges in formulating large volumes of parenteral such as achieving drug substance and excipient compatibility, are expected to hinder market growth over the forecast period.

Large Volume Parenteral (LVP) Industry Segmentation

As per the scope of the report, large-volume parenteral are dosages of more than 100 ml volumes of intravenous solutions commonly prescribed to correct fluid and electrolyte disturbances, nutrition, or to act as a vehicle for administering drugs to the body. Commonly used large-volume parenteral preparations include infusions of amino acid, mannitol, dextrose, lactated ringer injection, ringer's injection, and sodium chloride injection. The Large Volume Parenteral (LVP) Market is Segmented by Volume (100 ml - 250 ml, 250 ml - 500 ml, 500 ml - 1000 ml, 1000 ml - 2000 ml, and 2000 ml and more), Application (Therapeutic Injections, Fluid Balance Injections, and Nutritious Injections), Type of Packaging (Bottles and Bags), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.